Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence and Food-Effect Study of DopaSnap
NCT04236921Phase 1Completed
- Sponsor
- Riverside Pharmaceuticals
- Start
- Jul 2019
- Primary completion
- Sep 2019
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DopaSnap in Parkinson's disease (PD) (5 arms), sponsored by Riverside Pharmaceuticals. Primary endpoints: Rate and extent of absorption (AUC, Cmax) and Effect of food on the pharmacokinetics. Started Jul 2019; status: completed.
02
Drugs
DopaSnap
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04236921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04236921.